Compounds developed using Prous Institute Symmetry® Drug Discovery Platform open new avenues in cancer treatment Prous Institute for Biomedical Research has announced the recent publishing of its new WIPO patent application. The cited compounds figured among the new magnolol and honokiol derivatives obtained at the Prous Institute for Biomedical Research that have shown inhibitory activ...

Barcelona, January 12, 2012 – Prous Institute for Biomedical Research is proud to announce the nomination call for the 2012 Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery. Following their tradition of drug discovery science and technology, Prous Institute has donated the award biennially since 2004, acknowledging outstanding achievements in the field of m...

SYMMETRY®, an ensemble of computational tools and methods, aims to replicate all the processes through which new drugs are discovered, developed and approved in a conventional laboratory. Drug repositioning has emerged as a useful strategy to overcome the challenge of decreasing productivity in drug R&D. SYMMETRY® provides a wide variety of innovative approaches to drug reposition...

Washington D.C., USA: The Food and Drug Administration's Center for Food Safety and Applied Nutrition(FDA/CFSAN) and Prous Institute for Biomedical Research (PIBR) will work jointly under a 5 year research collaboration agreement (RCA) to develop hypothesis based in silico predictive tools that are consistent with CFSAN's and FDA’s Critical Path Initiative.This research will benefit CFSAN, t...

Washington D.C., USA: Prous Institute for Biomedical Research will be jointly presenting a scientific poster with the US FDA Center for Drug Evaluation and Research (CDER) at the Annual Meeting of the Society of Toxicology in Washington D.C.. The poster is titled: “Computational Modeling for QT Prolongation: A Drug Cardiovascular Safety Endpoint of Paramount Importance”. The poster wil...